Actuate Therapeutics Inc (ACTU)
Automate Your Wheel Strategy on ACTU
With Tiblio's Option Bot, you can configure your own wheel strategy including ACTU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACTU
- Rev/Share 0.0
- Book/Share 0.2085
- PB -34.8356
- Debt/Equity 0.0
- CurrentRatio 0.4641
- ROIC 5.0853
- MktCap 178342709.0
- FreeCF/Share -1.088
- PFCF -8.4069
- PE -7.0036
- Debt/Assets 0.0
- DivYield 0
- ROE 0.8889
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ACTU | Craig Hallum | -- | Buy | -- | $21 | April 22, 2025 |
| Initiation | ACTU | H.C. Wainwright | -- | Buy | -- | $20 | March 17, 2025 |
News
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the online publication of the abstract accepted as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30-June 3, in Chicago, Illinois.
Read More
About Actuate Therapeutics Inc (ACTU)
- IPO Date 2024-08-13
- Website https://actuatetherapeutics.com
- Industry Biotechnology
- CEO Mr. Daniel M. Schmitt
- Employees 10